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Abstract Although prostate cancer is one of the most
common cancers in men, the genetic defects underlying its
pathogenesis remain poorly understood. DNA damage
repair mechanisms have been implicated in human cancer.
Accumulating evidence indicates that the fidelity of the
response to DNA double-strand breaks is critical for
maintaining genome integrity. RAD51 is a central player in
double-strand break repair via homologous recombination,
and its alterations may confer and increase the risk of
cancer. RAD51 functioning depends on the indirect or
direct interactions with BRCA1 and BRCA2. To evaluate
the contribution of RAD51 to sporadic prostate cancer, loss
of heterozygosity (LOH) for chromosomal region 15q14-
21.1 (RAD51 locus) was determined and compared to LOH
in 17q21.31 (BRCA1 locus) and 13q12.3-13.1 (BRCA2
region). DNA was isolated from prostate biopsies and
matched peripheral blood of 50 patients. The regions
15q14-21.1, 17q21.31, and 13q12.3-13.1 were examined
using microsatellite markers on chromosome 15 (D15S118,
D15S214, D15S1006), chromosome 17 (D17S855,
D17S1323), and chromosome 13 (D13S260, D13S290),
respectively. The LOH in tumors was analyzed by PCR
with fluorescently labeled primers and an ABI PRISM 377
DNA Sequencer. Allele sizing was determined by GeneS-
can version 3.1.2 and Genotyper version 2.5 software
(Applied Biosystems, USA). LOH was identified in 57.5,
23, and 40 % for chromosomal regions 15q14-21.1,
17q21.31, and 13q12.3-13.1, respectively. Twenty-six
percent of studied cases manifested LOH for at least one
marker in 15q14-21.1 exclusively. A significant correlation
was found between LOH for studied region and PSAD
(prostate-specific antigen density). The findings suggest
that RAD51 may be considered as a prostate cancer sus-
ceptibility gene.
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Introduction
Prostate cancer is the second most common cancer to affect
males worldwide. This tumor is one of the most frequently
registered cancers among men in Poland, and cases of
prostate cancer represent above 14 % of all cancer mor-
bidity and 8 % of cancer mortality among men [1]. As
prostate cancer exhibits a diverse spectrum of behavior,
management of the disease is controversial [2]. Prostate-
specific antigen (PSA) is considered to be the most
remarkable prostate tumor marker. However, there is no
clear evidence of a relationship between mean PSA levels
at screening and the incidence or the rate of cancer
detection. Hence, improved biomarkers are needed to
enhance prediction of PSA. Various candidates have been
proposed to increase the value of PSA as a diagnostic and
prognostic marker [3–8]. However, unlike some human
malignancies, the etiology of prostate cancer does not
appear to be associated with a specific genetic suscepti-
bility but rather with multiple gene loci, each indepen-
dently conferring a low but cumulative risk. Meta-analysis
and genome-wide association studies (GWAS) have
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mapped the loci for prostate cancer susceptibility to several
chromosomes, and although putative candidate genes have
also been suggested, their significance for prostate cancer
remains unknown [9, 10].
Numerous studies describe an association between
mutations in DNA repair genes and neoplastic transfor-
mation. Mutations in BRCA1, BRCA2, BRIP1/FANCCJ,
CHEK2, MMR, and NBS1 have been found to confer an
increased risk of prostate cancer [11–20]. The response of
cells to DNA damage and their ability to maintain genomic
stability by DNA repair are critical for preventing cancer
initiation and progression. The most dangerous class of
genetic material damage is the double-strand break (DSB).
The key mode of DNA double-strand break repair includes
homologous recombination (HR), which precisely restores
the genomic sequence of the broken DNA ends by using
sister chromatids as a template for repair [21–23].
Although a plethora of proteins participate in the HR
repair of double-strand breaks, a crucial role is played by
RAD51, a mammalian homolog of bacterial RecA, an
evolutionarily conserved recombinase encoded by the
RAD51 gene located on human chromosome 15q15.1.
RAD51 co-localizes with BRCA1 and BRCA2 protein
within nuclear foci in mitotic cells. The foci have been
observed to contain BRCA1 together with the BRCA1-
binding protein BARD1, both before and after DNA
damage. RAD51 foci appear during the S-phase and are
required to initiate stalled or broken DNA replication forks.
RAD51 recombinase forms a direct association with
BRCA2, which is essential for normal recombination and
genome stability, as the interaction between BRCA2 and
RAD51 is fundamental for error-free HR in response to
DSBs. While BRCA2 is directly involved in RAD51-me-
diated repair, BRCA1 acts upstream from this pathway and
is thought to be required for the transport of RAD51 from
the cytoplasm into the nucleus and sites of DNA damage.
BRCA2 contains nuclear localization signals not found in
RAD51, supporting the notion that BRCA2 also facilitates
RAD51 transport into the nucleus. The direct interactions
of RAD51 and BRCA1 have not yet been fully elucidated,
despite gene expression profiling and network modeling
revealing a complex heterogeneity in the mechanisms of
BRCA1 involvement in tumorigenesis [24, 25].
The limited understanding of the genetic elements gov-
erning prostate cancer progression demands further studies
of its predisposing genes. Since genome instability is a
hallmark of a malignant phenotype and a driving force for
tumorigenesis, investigations of genes involved in DNA
double-strand breaks merit special interest. Although
germline mutations and LOH in BRCA1 and BRCA2 genes
have been detected in mutation carriers, no data currently
exist concerning the role of RAD51 in sporadic prostate
cancer [26, 27]. Hence, the aim of the present study is to
determine whether loss of heterozygosity (LOH) in RAD51,
BRCA1, and BRCA2 contributes to the sporadic prostate
cancer. Loss of heterozygosity for chromosomal regions
15q14-21.1, 17q21.31, and 13q12.3-13.1 was assessed by
seven microsatellite markers. The relationships between the
clinicopathological parameters of prostate adenocarcinoma
and LOH in studied chromosomal regions were examined.
Patients and methods
Patients and tissue samples
Peripheral blood and prostate adenocarcinoma biopsies
were collected at the Second Department of Urology,
Medical University of Lodz, Poland, between October
2009 and December 2011. All samples were obtained from
the peripheral zone of the prostate gland in patients who
underwent transrectal ultrasound (TRUS)-guided prostate
biopsy. After (TRUS)-guided prostate biopsy, the tissue
samples were placed in RNAlater solution (Qiagen, Inc.,
Chatsworth, CA, USA) and stored at -70 C until further
analysis. Blood samples from each patient were collected
on EDTA and frozen.
All tumor specimens were routinely assessed clinico-
pathologically for cancer stage and Gleason score by
independent pathologists. All other data were taken from
patients by diagnostic and epidemiology questionnaires.
The following characteristics were recorded: age of
patients, the level of prostate-specific antigen PSA, i.e.,
total PSA (PSAT) and free PSA (PSAF) in the serum of
patients measured at the time of diagnosis, and PSA density
(PSAD) for tumor tissue and prostate volume. None of the
patients had undergone hormonal therapy, radiotherapy, or
chemotherapy prior to surgery. Samples were obtained in
accordance with ethical and legal requirements. Informed
consent was obtained from patients, and the Independent
Ethical Committee of the Medical University of Lodz,
Poland, approved this study (RNN/59/09/KE).
In total, 50 patients with prostate adenocarcinoma were
recruited for this study. The clinical characteristics of the
studied material are given in Table 1.
DNA isolation
The DNA from prostate biopsies was isolated using TRI
Reagent (Sigma-Aldrich, USA). The DNA from periph-
eral blood of patients with prostate adenocarcinoma was
isolated using AxyPrepTM Blood Genomic DNA Miniprep
Kit (Axygen, USA) as a reference. DNA purity and
quantity were estimated by UV spectroscopy (Eppendorf
BioPhotometer TM Plus, Eppendorf, Germany). DNA was
identified by a ratio of 260/280 nm ranged 1.8–2.0.
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PCR conditions and primers
Genetic alterations for chromosomal regions: 15q14-21.1,
17q21.31, and 13q12.3-13.1 were analyzed for seven
microsatellite markers. Information about the microsatellite
markers and the sequences for all the primers for LOH
analysis was obtained from the National Center for
Biotechnology Information—NCBI (www.ncbi.nlm.nih.
gov). The primers were synthesized and labeled fluores-
cently by Applied Biosystems (USA). Polymerase chain
reaction (PCR) was carried out in a 10 ll reaction volume
containing 50 ng genomic DNA, 19 Solis Biodyne Buffer
B1, 3U HOT FIREPol DNA polymerase, 200 ll
GeneAmpdNTP Mix, 2 mM MgCl2, and 10 pmol/ll pri-
mers, of which one was end-labeled with 6-FAM or TET
phosphoramidite dye. PCR reagents were obtained from
Solis Biodyne (Estonia) and Applied Biosystems (USA).
Each microsatellite marker was amplified at its own
specific annealing temperature to optimize the PCR reac-
tion. Profile times and temperatures were as follows:
12 min at 95 C; 30 amplification cycles comprising
denaturation for 15 s at 95 C, primer annealing for 30 s at
55 C (for microsatellite markers: D15S118, D15S214,
D15S1006, D17S1323, D13S260) or 51 C (for
microsatellite markers D17S855, D13S290), elongation for
30 s at 72 C; 10 min for 72 C. Amplification was per-
formed in a GeneAmp 2400 thermal cycler (PerkinElmer,
USA). Localization of the analyzed microsatellite markers
and primer sequences are presented in Table 2.
LOH analysis
PCR products were electrophoresed on polyacrylamide gel
(5 % Long Ranger) containing 6 M urea and 1 9 TBE
(10 9 TBE: Tris borate, EDTA, pH 8.0). After PCR, the
samples were mixed with stop solution containing deion-
ized formamide, GeneScan-350 TAMRA Size Standard,
and loading buffer (blue dextran, EDTA), denatured, and
chilled on ice. Three microliters of each sample mixture
was applied in each well and run on an ABI PRISM 377
DNA Sequencer (Applied Biosystems, USA). The data
were collected automatically. Allele sizing was determined
by GeneScan v. 3.1.2 and Genotyper v. 2.5 software (Ap-
plied Biosystems, USA). Amplification of microsatellite
markers will yield one or two major allele peaks,
depending upon whether the individual is homozygous
(non-informative cases) or heterozygous (informative
cases) for that marker. LOH was defined as loss or C50 %
reduction in either allele in cancer compared with periph-
eral blood derived from the same patient. Allele ratios were
calculated for informative cases as described by Cawkwell
et al. [28] according to the formula T1 9 N2/T2 9 N1,
where T1 and N1 are the values of the shorter length allele
and T2 and N2 of the longer length allele for the tumor
(T) and normal (N) sample, respectively. A representative
sample with LOH in D15S118 and D15S214 microsatellite
markers for 15q14-21.1 region in prostate cancer as com-
pared to normal tissue is presented in Fig. 1. For each
prostate cancer sample, fractional allele loss (FAL) index
Table 1 Clinical characteristics of study subjects
Age (year)
Range 55–86
Mean ± SD 71.2 ± 8.6
Median 72
\72 24 (48 %)
C72 26 (52 %)
PSAT (ng/ml)
Range 4.58–1489
Mean ± SD 104.04 ± 251.28
Median 17.37
C4–10 15 (30 %)
C10–20 11 (22 %)
[20 24 (48 %)
PSAF/PSAT
Range 0.05–0.79
Mean ± SD 0.19 ± 0.13
Median 0.16
\0.16 24 (48 %)
C0.16 26 (52 %)
PSAD (ng/ml)
Range 0.08–56.4
Mean ± SD 2.72 ± 8.51
Median 0.29
\0.15 8 (16 %)
C0.15 42 (84 %)
Prostate volume (ml)
Range 20.7–191
Mean ± SD 57.72 ± 35.91
Median 47.25
\50 28 (56 %)
C50 22 (44 %)
Gleason score
4 2 (4 %)
6 9 (18 %)
7 18 (36 %)
8 11 (22 %)
9 9 (18 %)
10 1 (2 %)
Cancer stage
T1 12 (24 %)
T2 14 (28 %)
T3 12 (24 %)
T4 12 (24 %)
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was also calculated reflecting the ratio of total number of
chromosomal loci with LOH to the total number of infor-
mative loci examined.
Statistical analysis
The statistical significance of LOH for at least one
microsatellite marker identified concomitantly in three
studied regions was tested using Spearman rank correlation
test. Statistical significance of the relationship between the
presence of LOH and clinicopathological parameters was
performed using Fisher’s exact test. P\ 0.05 was consid-
ered statistically significant. For associations between
clinical variables of patients (age at diagnosis, total PSA
(PSAT), total/free PSA value (PSAF/PSAT), PSA density
(PSAD), prostate volume), histopathological parameters
(according to TNM classification and Gleason score), and
FAL index values, a Mann–Whitney U test or Kruskal–
Wallis test was performed. The correlation between pres-
ence of LOH and the level of PSA and patients age was
examined using linear regression. The statistical analysis
was carried out using the Statistica for Windows, v. 5.
Results
The loss of heterozygosity (LOH) was evaluated using the
microsatellite markers D15S118, D15S214, and D15S1006 for
chromosomal region 15q14-21.1, D17S855, and D17S1323 for
chromosomal region 17q21.31, and D13S260 and D13S290 for
chromosomal region 13q12.3-13.1. The LOH studies rely on the
detection of the loss of a single copy of the two alleles orC50 %
reduction in either allele. Those with detectable heterozygous
alleles were defined as informative cases. Frequency of LOH for
studied microsatellite markers in prostate cancer is presented in
Table 3.
As shown in Table 4, genomic deletion detected by
allelic loss varied according to the region tested. In the case
of chromosomal region 15q14-21.1, loss of heterozygosity
was observed in 57.5 %, i.e., in 23 out of 40 heterozygous
patients. In the region 15q14-21.1, the highest incidence of
LOH, corresponding to 60 % of informative cases, was
found for microsatellite marker D15S214 located at RAD51
locus. In the 17q21.31 region, LOH occurred in 23 %, i.e.,
in 7 out of 30 heterozygous patients, and in the 13q12.3-
13.1 region in 40 %, i.e., in 14 out of 35 heterozygous
patients. Twenty-six percent of the studied prostate cancer
Table 2 Characteristics of the analyzed microsatellite markers and PCR reaction (http://www.ncbi.nlm.nih.gov)
Microsatellite marker Chromosomal region (gene) Position Primer sequence Dye Product sizes (bp)
D15S118 15q14 12 996 879 (?) TCAAAGACCCATATCAACCA 6-FAM 218–232
(–) GTGCTGAAAAGCGACACTTA
D15S214 15q15.1 (RAD51) 17 166 170 (?) GGAGGGCACTTCCTGAG TET 260–274
(–) GCCTGGCATCACGACT
D15S1006 15q21.1 24 439 646 (?) AGGGAATACTTCAAAACTC 6-FAM 212–224
(–) CCACTTGGCTATGGTGAAT
D17S855 17q21.31 (BRCA1) 37 861 601 (?) GGATGGCCTTTTAGAAAGTGG 6-FAM 142–156
(–) ACACAGACTTGTCCTACTGCC
D17S1323 37 894 900 (?) TAGGAGATGGATTATTGGTG TET 153–161
(–) AAGCAACTTTGCAATGAGTG
D13S260 13q12-13 (BRCA2) 13 503 800 (?) AGATATTGTCTCCGTTCCATGA 6-FAM 155–171
(–) CCCAGATATAAGGACCTGGCTA





Fig. 1 Example of LOH analysis for 13q12-13 region in prostate
cancer
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Table 3 Frequency of LOH in prostate cancer for studied microsatellite markers
Sample no. D15S118 D15S214 D15S1006 D17S855 D17S1323 D13S260 D13S290 FAL index
1 ni ni ni NG NG NG ni 0
2 NG NG NG ni NG ni NG 0
3 ni ni ni NG ni LOH LOH 0.667
4 NG LOH NG ni ni ni ni 0.333
5 ni LOH NG NG ni NG NG 0.5
6 ni ni NG ni ni NG LOH 0.5
7 ni LOH ni ni NG ni ni 0
8 NG LOH LOH ni NG ni ni 0.667
9 ni ni NG ni ni NG ni 0
10 NG ni ni ni ni ni NG 0.5
11 NG ni ni ni ni NG ni 0.667
12 ni LOH ni ni NG LOH ni 1
13 NG NG ni NG ni LOH ni 0.4
14 ni ni ni NG ni ni ni 0.6
15 ni ni ni NG ni ni NG 0.333
16 NG ni ni ni ni ni ni 0.2
17 NG ni ni ni ni LOH ni 0
18 ni ni LOH ni ni LOH ni 1
19 LOH LOH ni ni NG ni ni 0
20 ni ni ni NG ni NG ni 0.5
21 ni NG ni ni ni ni LOH 0
22 ni ni ni ni ni NG NG 1
23 NG LOH ni ni NG NG ni 0
24 NG LOH ni ni ni LOH ni 0
25 LOH LOH ni LOH ni LOH ni 0.75
26 NG LOH ni ni ni ni NG 0
27 NG ni ni LOH NG ni ni 0
28 LOH NG ni LOH ni ni ni 0
29 ni LOH ni ni ni ni ni 0.5
30 ni ni ni NG ni ni NG 0.5
31 LOH ni ni NG ni LOH LOH 0.5
32 LOH ni LOH NG ni ni ni 0
33 LOH NG ni ni ni ni ni 0.667
34 LOH LOH ni NG ni NG NG 1
35 LOH NG ni LOH ni NG LOH 0.75
36 ni ni ni ni ni NG NG 0.25
37 NG ni ni NG NG ni ni 0
38 NG ni ni ni NG NG LOH 0
39 ni ni ni ni LOH NG ni 0
40 ni LOH ni ni NG ni ni 0.25
41 NG LOH NG LOH NG NG ni 0
42 ni NG ni ni ni NG NG 0.5
43 ni NG ni NG ni NG NG 0.25
44 ni LOH ni ni ni ni ni 0.333
45 ni NG LOH ni ni NG LOH 0.333
46 ni ni NG ni ni ni ni 0.667
47 ni ni ni ni ni NG NG 0
48 LOH ni ni NG LOH Ni LOH 0.667
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cases displayed LOH for at least one microsatellite marker
at 15q14-21.1 region, without LOH in the 17q21.31 or
13q12.3-13.1 regions. The LOH for at least one
microsatellite marker in the 17q21.31 and 13q12.3-13.1
regions, without LOH in 15q14-21.1 region, was estimated
as only 6 and 19 %, respectively.
The association of the LOH in studied chromosomal
regions with clinicopathological characteristics of patients
was analyzed using Fisher’s exact test. A significant cor-
relation was found between LOH in chromosomal regions
15q14-21.1 and 13q12.3-13.1 and PSA density (PSAD)
(Table 5).
Table 3 continued
Sample no. D15S118 D15S214 D15S1006 D17S855 D17S1323 D13S260 D13S290 FAL index
49 ni NG NG ni NG NG ni 0
50 ni ni NG NG NG ni NG 0.333
LOH loss of heterozygosity, NG heterozygous without LOH, ni non-informative cases (homozygous)
Table 4 Incidence of LOH at 15q14-21.1, 17q21.31, and 13q12-13 chromosomal regions in prostate cancer
Chromosomal region Number of informative case/studied cases (%) Number of tumor with LOH/informative cases (%)
15q14-21.1 40/50 (80 %) 23/40 (57.5 %)
17q21.31 30/50 (60 %) 7/30 (23 %)
13q12.3-13.1 35/50 (70 %) 14/35 (40 %)
Table 5 Relationship between
LOH at 15q14-21.1, 17q21.31,




Clinical characteristics Chromosomal region
15q14-21.1 17q21.31 13q12.3-13.1
I N LOH P I N LOH P I N LOH P
Tumor cases 40 17 23 30 23 7 35 21 14
Age
\72 18 7 11 0.755 16 11 5 0.399 21 13 8 [0.999
C72 22 10 12 14 12 2 14 8 6
PSAT (ng/ml)
C4–10 14 6 8 0.088 8 7 1 0.284 11 5 6 0.383
[10–20 6 5 1 5 5 0 9 7 2
[20 20 6 14 17 11 6 15 9 6
PSAF/PSAT
\0.16 18 7 11 0.755 15 13 2 0.390 17 11 6 0.733
C0.16 22 10 12 15 10 5 18 10 8
PSAD (ng/ml)
\0.15 8 2 6 0.049 7 4 3 0.306 7 1 6 0.001
C0.15 32 15 17 23 19 4 28 20 8
Prostate volume (ml)
\50 22 11 11 0.348 14 11 3 [0.999 21 16 5 0.033
C50 18 6 12 16 12 4 14 5 9
Gleason score
\7 15 7 8 0.749 6 4 2 0.603 10 6 4 [0.999
C7 25 10 15 24 19 5 25 15 10
Cancer stage
T1–T2 21 8 13 0.749 13 11 2 0.427 19 11 8 [0.999
T3–T4 19 9 10 17 12 5 16 10 6
P\ 0.05 indicates significant association, I Informative cases, NG heterozygous without LOH (negative
cases)
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Mann–Whitney U test revealed statistically significant
differences between FAL index levels and PSA density
(Fig. 2). There was no statistically significant correlation
between FAL index levels and patients’ age, free to total
PSA value, prostate volume, Gleason score, and TNM
classification (Mann–Whitney U test) as well as total PSA
level (Kruskal–Wallis test). Neither correlation between
age of patients with LOH and PSA level, free to total PSA
value nor PSA density was identified (data not shown).
Discussion
Although the contribution of the homologous recombina-
tion mediators BRCA1 and BRCA2 to prostate cancer has
been previously investigated, this is the first study to
address the importance of RAD51 genetics in the occur-
rence of sporadic prostate cancer [26, 29]. RAD51 is a
relatively small and rigid protein playing a basic role in the
high-fidelity DNA repair mechanism of homologous
recombination via homology search and DNA strand
exchange. RAD51 appears vital for cell survival, as its
depletion results in embryonic lethality. It has been highly
conserved throughout evolution, and until now, no single
mutation has been detected in the coding region of RAD51
in any type of cancer. However, a strong correlation has
been identified between its expression level and both can-
cer development and progression. It is suggested that
overexpression of RAD51 suppresses recombination
defects [24, 30–32].
The progression of prostate cancer as in other malig-
nancies is characterized by increased genetic and epige-
netic aberrations. Of particular interest are germline
polymorphisms and allelic imbalances, which may affect
tumor suppressor genes and oncogenes [8, 33–35].
The BRCA1 and BRCA2 genes, whose best known
function is concerned with the DNA damage response,
have been reported to contribute to prostate cancer,
although to different extents. The Breast Cancer Linkage
Consortium report increased prostate cancer risk of BRCA1
mutation carriers below the age of 65, with a relative risk
of 1.82, but no increase in those aged over 65. For BRCA2
mutation carriers, the relative risk of developing prostate
cancer was estimated as 4.65, rising to 7.33 for men
younger than 65 years [36–39]. Uchida et al. [40] identified
LOH in the BRCA1 gene in primary prostate cancer using
seven highly polymorphic tandem repeat markers on
chromosome 17q21, in addition to an analysis of the whole
coding region of the BRCA1 gene. Four of the 24 prostate
cancer specimens revealed the presence of LOH at one or
more loci, all of which were found to be at stage D with
poor histological differentiation. One of the 24 cases
showed a germline mutation of the BRCA1 gene. Willems
et al. [41] observed LOH at BRCA2 in 10 of 14 tumors
from BRCA2 mutation carriers (71 %), but no LOH in
BRCA1 in four tumors from BRCA1 mutation carriers.
Assuming that LOH occurs only because the cancer is
caused by the germline mutation, carriers of BRCA2
mutations are at 3.5-fold increased risk of prostate cancer.
Similarly Edwards et al. [37] identified LOH in the
majority of tumors of BRCA2 mutation carriers. On the
other hand, Willems-Jones et al. [42] note that high-grade
prostatic intraepithelial neoplasia, believed to be a pre-
cursor to prostate adenocarcinoma in some cases, does not
display LOH at the mutation locus in BRCA2 mutation
carriers with aggressive prostate cancer.
The present study reveals in prostate cancer the presence
of LOH in 57.5, 23, and 40 % for chromosomal regions
15q14-21.1, 17q21.31, and 13q12.3-13.1, respectively. In
the region 15q14-21.1, the highest incidence of LOH cor-
responding to 60 % was found for microsatellite marker
D15S214 located at RAD51 locus. Hence, chromosomal
region 15q14-21.1 was found to display a higher incidence
of LOH than BRCA loci, especially BRCA2, which is con-
sidered a prostate tumor suppressor. In prostate cancer,
26 % of cases manifested LOH at 15q14-21.1 chromosomal
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Fig. 2 Box-and-whisker plot, representing the a mean and b median
FAL index values for the PSAD in prostate cancer
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region exclusively, without LOH in the 17q21.31 or
13q12.3-13.1 regions. Interestingly, LOH in 15q14-21.1
chromosomal region appeared to be related to PSA density.
Conclusions
The high frequency of allelic losses at the RAD51 locus
indicates the important role played by this gene in prostate
cancer and sheds light on the novel perspective of genetic
changes associated with its development. RAD51 dis-
played a higher incidence of LOH than BRCA2, which is
considered a prostate tumor suppressor. A better under-
standing of the molecular basis of prostate cancer may
permit a more accurate assessment of this disease.
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